Real-world safety profile of riluzole: a systematic analysis of data from the FAERS database and case reports.
Zhuo SunXin LiuPengjiao AnBo ZhangPublished in: Expert opinion on drug safety (2023)
Strong ADRs between riluzole and pancreatitis were identified, which reminds clinicians to monitor patients carefully. For patients with respiratory symptoms, clinicians should pay attention to distinguish the cause of their occurrence, and take appropriate measures. Beware that riluzole may increase the risk of inflammatory reactions and inappropriate vasopressin secretion and hyponatremia due to respiratory failure.
Keyphrases
- respiratory failure
- end stage renal disease
- palliative care
- newly diagnosed
- ejection fraction
- chronic kidney disease
- risk assessment
- working memory
- extracorporeal membrane oxygenation
- mechanical ventilation
- oxidative stress
- peritoneal dialysis
- electronic health record
- intensive care unit
- artificial intelligence
- patient reported